Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
Tango Therapeutics is seeking an innovative and collaborative leader to serve as Vice President, Safety and Pharmacovigilance. This individual will provide strategic direction and day-to-day leadership for the Medical Safety Science function. This individual will manage the Pharmacovigilance team and play an important role in guiding the company’s safety strategy, supporting global regulatory interactions, contributing to portfolio governance, and informing long-term planning. The ideal candidate brings strong clinical knowledge, broad pharmacovigilance expertise, and the ability to work effectively across teams and with external stakeholders.
Your Role:
- Lead and oversee all pharmacovigilance and risk management activities for Tango’s clinical programs
- Develop and execute comprehensive safety science strategies for oncology drug development programs from preclinical through post-market surveillance
- Provide safety expertise and risk-benefit assessments to support go/no-go decisions for oncology programs
- Represent Tango in interactions with health authorities, including preparing and presenting safety data in regulatory meetings
- Provide medical safety expertise and leadership across all clinical development activities, including protocols, CSRs, IBs, ICFs, and regulatory briefing books
- Oversee signal detection, safety surveillance, and benefit-risk assessments, implementing risk mitigation strategies as needed
- Direct the preparation and review of key safety documents, including DSURs, SUSARs, periodic and annual safety reports, and regulatory communications
- Develop and manage PV budgets, ensuring alignment with corporate objectives
- Oversee the development and execution of safety processes, standards, and technologies to improve efficiency, scalability, and scientific quality
- Direct the preparation of safety sections for regulatory submissions including INDs, NDAs, BLAs, and periodic safety reports
- Oversee the development of safety monitoring plans and data safety monitoring boards for clinical trials
- Build and lead a high-performing global safety science organization
- Lead cross-functional safety teams and collaborate with clinical development, regulatory affairs, medical affairs, and commercial teams
- Mentor and develop safety professionals, fostering a culture of scientific rigor and patient focus
- Represent the company at regulatory meetings, scientific conferences, and industry forums
- Collaborate with external partners including CROs, academic institutions, and regulatory consultants
- Champion patient safety as a core organizational value
What You Bring:
- MD and 10+ years of experience in pharmacovigilance, safety science, or related roles within the pharmaceutical/biotech industry
- Deep understanding of oncology drug development, including novel therapies (immunotherapy, targeted therapy, cell therapy)
- Strong strategic thinking and business acumen
- Excellent communication skills with ability to present complex safety data to various stakeholders
- Expertise in global pharmacovigilance regulations, safety surveillance, reporting, and risk management strategies
- Experience with regulatory authority interactions, safety database applications, and safety signal detection methodologies
- Strong leadership skills with a proven track record of building and managing safety teams
- Effective communicator with excellent written, verbal, and presentation skills
- Ability to thrive in a fast-paced, high-growth environment, balancing multiple priorities while maintaining a strong commitment to ethical standards
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Similar Jobs
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
